91 related articles for article (PubMed ID: 311684)
1. Dose-dependent adjuvant effects of Bacillus Calmette-Guérin on tumor immunity in Lewis rats.
Davies M; Sabbadini E
Cancer Res; 1979 Mar; 39(3):959-65. PubMed ID: 311684
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of established micrometastases with Bacillus Calmette-Guérin tumor cell vaccine.
Hanna MG; Peters LC
Cancer Res; 1978 Jan; 38(1):204-9. PubMed ID: 201374
[TBL] [Abstract][Full Text] [Related]
3. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
Braun DP; Mokyr MB; Dray S
Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
[TBL] [Abstract][Full Text] [Related]
4. Preoperative intralesional Bacillus Calmette-Guérin for mammary adenocarcinoma in rats.
Lee YT
Cancer Res; 1977 Oct; 37(10):3679-83. PubMed ID: 908015
[TBL] [Abstract][Full Text] [Related]
5. Conditions for effective Bacillus Calmette-Guérin immunotherapy of postsurgical metastases of 13762A rat mammary adenocarcinoma.
Kreider JW; Bartlett GL; Boyer CM; Purnell DM
Cancer Res; 1979 Mar; 39(3):987-92. PubMed ID: 427785
[TBL] [Abstract][Full Text] [Related]
6. Influence of preexisting tumor immunity on Bacillus Calmette-Guérin immunotherapy of guinea pigs with both regional and disseminated tumor.
Jessup JM; Riggs CW; Hanna MG
Cancer Res; 1977 Aug; 37(8 Pt 1):2565-73. PubMed ID: 872084
[No Abstract] [Full Text] [Related]
7. Therapy in an intracerebral murine glioma model, using Bacillus Calmette-Guérin, neuraminidase-treated tumor cells, and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
Albright L; Madigan JC; Gaston MR; Houchens DP
Cancer Res; 1975 Mar; 35(3):658-65. PubMed ID: 234790
[TBL] [Abstract][Full Text] [Related]
8. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R;
Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
[TBL] [Abstract][Full Text] [Related]
9. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis.
Haile M; Schröder U; Hamasur B; Pawlowski A; Jaxmar T; Källenius G; Svenson SB
Vaccine; 2004 Mar; 22(11-12):1498-508. PubMed ID: 15063575
[TBL] [Abstract][Full Text] [Related]
10. Cross-reactivity between Bacillus Calmette-Guérin and Rous Virus-induced sarcoma detected in rats by tube leukocyte adherence inhibition assay.
Holán V; Chutná J; Hasek M
Cancer Res; 1979 Feb; 39(2 Pt 2):593-6. PubMed ID: 216490
[TBL] [Abstract][Full Text] [Related]
11. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
[TBL] [Abstract][Full Text] [Related]
12. Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guérin.
Dubois JB; Serrou B
Cancer Res; 1976 May; 36(5):1731-4. PubMed ID: 773530
[TBL] [Abstract][Full Text] [Related]
13. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
Pan CW; Shen ZJ; Ding GQ
J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
[TBL] [Abstract][Full Text] [Related]
14. Endogenous production of cytotoxic factors in serum of BCG-primed mice by monophosphoryl lipid A, a detoxified form of endotoxin.
Bennett JA; Peters JH; Chudacoff R; McKneally MF
J Biol Response Mod; 1988 Feb; 7(1):65-76. PubMed ID: 3373236
[TBL] [Abstract][Full Text] [Related]
15. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
16. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
Vaage J
Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
[TBL] [Abstract][Full Text] [Related]
17. Bacillus Calmette-Guérin and dinitrochlorobenzene immunotherapy of chemically induced bladder tumors.
Lamm DL; Harris SC; Gittes RF
Invest Urol; 1977 Mar; 14(5):369-72. PubMed ID: 844999
[TBL] [Abstract][Full Text] [Related]
18. Intralesional Bacillus Calmette-Guérin immunotherapy of canine venereal tumors.
Hess AD; Catchatourian R; Zander AR; Epstein RB
Cancer Res; 1977 Nov; 37(11):3990-4. PubMed ID: 143344
[TBL] [Abstract][Full Text] [Related]
19. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
[TBL] [Abstract][Full Text] [Related]
20. The role of B1 and B2 kinin receptors in oedema formation after long-term treatment with Mycobacterium bovis bacillus Calmette-Guérin (BCG).
Campos MM; Henriques MG; Calixto JB
Br J Pharmacol; 1997 Feb; 120(3):502-8. PubMed ID: 9031756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
